Atlas Trials

Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Clinical trial NCT07533305 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07533305
Sponsor
The First Affiliated Hospital of Henan University of Science and Technology
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
QL1706ESCCFirst-line Therapy
Start date
2026-05-01
Primary completion
2028-06-30
Enrollment
50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.